Results 11 to 20 of about 75,080 (214)
Peptide immunotherapy in experimental autoimmune encephalomyelitis [PDF]
We now have potent drugs available to treat the inflammatory component of multiple sclerosis (MS). However, not all patients respond, the drugs are not curative, and the associated risks to beneficial immune surveillance are considerable.
Stephen M Anderton
doaj +3 more sources
Experimental autoimmune encephalomyelitis
Jean Kanellopoulos
doaj +3 more sources
Experimental Autoimmune Encephalomyelitis (EAE) [PDF]
AbstractThe procedures described in this unit utilize murine models exclusively since murine EAE often results in a relapsing/remitting disease, similar to the early phase of most MS patients. EAE in the Lewis rat is a monophasic illness in which animals experience a single episode of paralysis from which most recover completely. This unit presents two
openaire +3 more sources
MyD88 Deficiency Protects Mice From Experimental Autoimmune Encephalomyelitis by Influencing Both Dendritic Cells and T Cells. [PDF]
This study investigates the role of MyD88 in dendritic cells (DCs) and T cells during experimental autoimmune encephalomyelitis (EAE). We found that MyD88 is highly expressed in DCs and CD4+ T cells in people with multiple sclerosis, and its deficiency impairs DC maturation, reduces pro‐inflammatory cytokine production, weakens DC–T cell interactions ...
Si W, Zhu G, Jiang Q, Ma X, Yang G.
europepmc +2 more sources
Induced Stem Cells as a Novel Multiple Sclerosis Therapy. [PDF]
Stem cell replacement is providing hope for many degenerative diseases that lack effective therapeutic methods including multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system. Transplantation of neural stem cells or
Guan, Yang-Tai +3 more
core +2 more sources
Our previous work demonstrated that vitamin D (VitD) reduces experimental autoimmune encephalomyelitis (EAE) disease severity in wild-type (WT) but not in T cell-specific glucocorticoid (GC) receptor (GR)-deficient (GRlck) mice.
Maud Bagnoud +7 more
doaj +1 more source
Emerging immunopharmacological targets in multiple sclerosis. [PDF]
Inflammatory demyelination of the central nervous system (CNS) is the hallmark of multiple sclerosis (MS), a chronic debilitating disease that affects more than 2.5 million individuals worldwide. It has been widely accepted, although not proven, that the
Abdolmohamad Rostami +182 more
core +2 more sources
Silencing miR-150 Ameliorates Experimental Autoimmune Encephalomyelitis
MiR-150 regulates maturation and differentiation of T cells but how it functions in multiple sclerosis (MS) is unclear. In miR-150 knockout (KO) mice, we examined the effect of miR-150 deletion on disease severity of experimental autoimmune ...
Zhaolan Hu +8 more
doaj +1 more source
Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). [PDF]
Matrix metalloproteinases (MMPs) have a crucial function in migration of inflammatory cells into the central nervous system (CNS). Levels of MMP-9 are elevated in multiple sclerosis (MS) and predict the occurrence of new active lesions on magnetic ...
Du, Sienmi +6 more
core +3 more sources
Background Hypomethylation of the cathepsin Z locus has been proposed as an epigenetic risk factor for multiple sclerosis (MS). Cathepsin Z is a unique lysosomal cysteine cathepsin expressed primarily by antigen presenting cells.
Euan R. O. Allan +9 more
doaj +1 more source

